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Helicobacter pylori is the primary cause of peptic ulcer
disease and an etiologic agent in the development of gas-
tric cancer. H. pylori infection is curable with regimens of
multiple antimicrobial agents, and antimicrobial resistance
is a leading cause of treatment failure. The Helicobacter
pylori Antimicrobial Resistance Monitoring Program
(HARP) is a prospective, multicenter U.S. network that
tracks national incidence rates of H. pylori antimicrobial
resistance. Of 347 clinical H. pylori isolates collected from
December 1998 through 2002, 101 (29.1%) were resistant
to one antimicrobial agent, and 17 (5%) were resistant to
two or more antimicrobial agents. Eighty-seven (25.1%)
isolates were resistant to metronidazole, 45 (12.9%) to clar-
ithromycin, and 3 (0.9%) to amoxicillin. On multivariate
analysis, black race was the only significant risk factor (p <
0.01, hazard ratio 2.04) for infection with a resistant H.
pylori strain. Formulating pretreatment screening strategies
or providing alternative therapeutic regimens for high-risk
populations may be important for future clinical practice.
T
he prevalence of Helicobacter pylori infection world-
wide is approximately 50% (1), as high as 80%–90%
in developing countries, and ≈35%–40% in the United
States (1). Approximately 20% of persons infected with H.
pylori  develop related gastroduodenal disorders during
their lifetime (1). H. pylori is an etiologic agent of peptic
ulcer disease, primary gastritis, gastric mucosa-associated
lymphoid-tissue lymphoma, and gastric adenocarcinoma
(2). The annual incidence of H. pylori infection is
≈4%–15% in developing countries, compared with
approximately 0.5% in industrialized countries (3).
Documented risk factors include low socioeconomic sta-
tus, overcrowding, poor sanitation or hygiene, and living
in a developing country (2). 
Eradication therapy of symptomatic H. pylori infection
substantially reduces the recurrence of associated gastro-
duodenal diseases. Therapy entails complicated regimens
of several antimicrobial agents for at least 2 weeks. In gen-
eral, triple therapy regimens usually entail two of the fol-
lowing antimicrobial agents: metronidazole, amoxicillin,
tetracycline, or clarithromycin in combination with a pro-
ton pump inhibitor or bismuth (4). The most common
causes of treatment failure are patient noncompliance and
antimicrobial resistance of the infecting H. pylori strain
(5). Quadruple regimens are used as a salvage therapy
when triple therapy regimens have failed (4). Pretreatment
resistance of H. pylori has been reported to compromise
the efficacy of treatment. For example, therapy regimens
containing metronidazole and clarithromycin fail in as
many as 38% and 55% of cases, respectively, when used to
treat infection with an organism resistant to one of these
antimicrobial agents (6). In addition, published data are
lacking that describe the effect conferred by polymicrobial
resistance on eradication success. 
The  Helicobacter pylori Antimicrobial Resistance
Monitoring Project (HARP) is a prospective, longitudinal
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of antimicrobial resistance in H. pylori isolates in the
United States. The network is positioned to document
emerging resistance and to assist physicians in formulating
therapy recommendations. We present the results of the
antimicrobial resistance monitoring and risk factor analy-
sis from data collected prospectively from 1998 through
2002. 
Materials and Methods
During the course of the study, HARP consisted of 11
hospital study sites across the United States. The first five
patients who sought treatment each month for esophago-
gastro duodenal endoscopy (EGD) as part of treatment for
H. pylori infection, confirmed by gastric biopsy, were
enrolled at each site. When fewer than five eligible study
participants were seen at a study center, those eligible were
enrolled. Written, signed consent was obtained from all
participants or their guardians. Culture of biopsied materi-
al for H. pylori was performed at the study site or at the
Atlanta Veterans Affairs Hospital. If primary isolation was
performed at the HARP study site, isolates were placed in
trypticase soy broth (TSB) supplemented with glycerol
and stored at –70°C. Isolates were sent to the Centers for
Disease Control and Prevention for antimicrobial resist-
ance testing. Samples forwarded to the Atlanta Veterans
Affairs Hospital for isolation were packed in 6 pounds of
dry ice and maintained at –70°C to –80°C until cultured
(up to 1 month). Each specimen was accompanied by a
standard case report form containing 145 variables of
demographic, clinical, and epidemiologic information. 
Laboratory Procedures 
Isolates were cultured on heart infusion agar (HIA)
with 5% rabbit blood at 37°C in a microaerobic atmos-
phere (10% CO2, 85% N2, 5% O2) for a minimum of 72
hours or until appearance of H. pylori colonies. Gastric
biopsy specimens were homogenized by using a micropes-
tle in a microcentrifuge tube, and the homogenates were
added to HIA with 5% rabbit’s blood and Skirrow media
and incubated at 37°C microaerobically for up to 2 weeks.
Presumptive H. pylori colonies were subcultured for fur-
ther testing. Isolates were confirmed as H. pylori if they
demonstrated typical morphologic features by dark-field
microscopy and if urease, oxidase, and catalase activities
were detected. Also, a polymerase chain reaction amplifi-
cation assay that used primers targeted at the ureA gene
provided confirmation (7). Antimicrobial susceptibility
testing was performed by the agar dilution method in
accordance with National Committee for Clinical
Laboratory Standards (NCCLS) protocols, except that
defibrinated rabbit blood was used instead of aged sheep
blood (8). For antimicrobial agents without an NCCLS-
recommended breakpoint, breakpoints were selected after
a review of the literature.
Data Collection and Analysis 
Case report forms and laboratory data were entered
into a MS Access 2000 database and analyzed by using
SAS, version 8.2 (SAS Institute, Cary, NC). We defined a
resistant case to be an HARP isolate that demonstrated
any detectable resistance to metronidazole, clar-
ithromycin, tetracycline, or amoxicillin. HARPstudy sites
were assigned to the following four regions: Northeast
(Washington, DC; New York, NY; and Philadelphia, PA),
South (Atlanta, GA; Nashville, TN; and Galveston, TX),
Midwest (Detroit, MI; Cleveland, OH; Indianapolis, IN;
and Milwaukee, WI), and West (Palo Alto, CA).
Differences between patients infected with resistant and
susceptible strains of H. pylori were assessed by using the
Fisher exact test, Mantel-Haenszel chi-square, or Student
t  test, as appropriate. A one-way analysis of variance
(ANOVA) was used to determine antimicrobial resistance
rate trends for clarithromycin and metronidazole. When
the difference in the number of study participants that har-
bored a resistant H. pylori infection and those who did not
for a given risk factor was <2, we chose to exclude the risk
factor from further analysis because of the possibility of
arriving at a spurious association caused by small cell-size
variations. This method enhanced the statistical reliability
of all possible exposure and resistance associations con-
sidered for multivariate modeling. Risk factors that met
these criteria were subjected to a chi-square score model
selection procedure to obtain the most significant and sta-
ble multivariate model. Multivariate analyses were per-
formed by using logistic regression to assess the
independent association of identified risk factors with any
detectable antimicrobial resistance using two different
models.
The first logistic regression model assessed significant
univariate risk factors for antimicrobial resistance. A sec-
ond logistic regression model was created that we condi-
tioned on geographic location of HARP site, previous
antimicrobial treatment for H. pylori infection, and antacid
use to resolve colinearity issues with race.
Results
Of 317 enrolled HARP study participants for whom
complete demographic information was available, 205
(65%) were male, 116 (37%) were white, 172 (54%) were
black, 14 (4%) were Asian, 3 (1%) were Native American,
and 12 (4%) were of other ethnic backgrounds. The medi-
an age was 57 years (range 3–94 years). Among males, 97
(31%) were white, 90 (28%) were black, and 9 (3%) were
Asian, 1 (0.3%) was Native American, and 8 (3%) were of
other ethnic backgrounds. Among females, 19 (6%) were
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were Native American, and 4 (1%) were of other ethnic
backgrounds. The most common endoscopic diagnoses for
conditions of HARP participants were gastric erosions,
gastritis, duodenal and gastric ulcers, and esophagitis
(Table 1). H. pylori resistance was not statistically associ-
ated with endoscopic findings.
Among 347 H. pylori isolates submitted to HARP from
1998 to 2002, 118 (34%) were resistant to >1 antimicrobial
agent, 101 (29%) H. pylori isolates were resistant to one
agent only, and 17 (5%) H. pylori isolates were resistant to
more than one antimicrobial agent. Three isolates were
resistant to amoxicillin (1%), 45 were resistant to clar-
ithromycin (13%), 87 were resistant to metronidazole
(25%), and no isolate was found to be resistant to tetracy-
cline. Multiple-agent resistance was observed for clar-
ithromycin and amoxicillin (1 isolate, 0.3%) and
clarithromycin and metronidazole (16 isolates, 5%). A test
of trend showed no significant trend for resistance to
metronidazole, but a significant trend (R2 = 0.76) was
noted for a decline in resistance to clarithromycin during
the study period (Figure). 
Most isolates were submitted by centers in the
Northeast region, followed by the South, Midwest, and the
West. Submitted H. pylori isolates from the Northeast
region had the highest frequency of single- and dual-agent
resistance (Table 2). The Midwest region submitted H.
pylori isolates with the second-highest single agent resist-
ance rate, while the southern region had the second-high-
est dual agent resistance rate. The highest proportion of H.
pylori isolates resistant to clarithromycin, metronidazole,
and amoxicillin was in the Northeast (Table 2). 
The four sites reporting the highest proportion of iso-
lates resistant to one agent were Indianapolis, Indiana;
Galveston, Texas; Philadelphia, Pennsylvania; and
Washington, DC (Table 3). Dual agent resistance was most
prevalent in Detroit, Michigan. Indianapolis had the high-
est overall resistance: 50% of all isolates submitted were
resistant to at least one agent. The Atlanta site reported the
highest proportion of clarithromycin-resistant isolates
(Table 3). The highest proportion of metronidazole resist-
ance was reported from the Indianapolis site. Isolates
resistant to amoxicillin were found in Nashville,
Tennessee, Philadelphia, and Washington, DC.
Demographic, clinical, and epidemiologic data were
analyzed for association with infection by a resistant H.
pylori strain. Results of univariate analysis of risk factors
for antimicrobial resistance are summarized in Table 4. On
univariate analysis, significant risk factors for H. pylori
resistance included past treatment of H. pylori infection
with clarithromycin, treatment of past H. pylori infection
for a second time in the past 5 years, treatment of past H.
pylori infection with clarithromycin more than once, and
treatment of past H. pylori infection with a proton pump
inhibitor more than once. No protective factors for resist-
ant H. pylori resistance approached significance. 
On multivariate analysis, the most significant risk fac-
tor for H. pylori resistance was previous treatment of H.
pylori infection within the past 5 years (Table 5).
Protective factors for H. pylori infection were treatment
with an antacid (Mylanta) and submission of specimens
from New York, Palo Alto, California, Atlanta, or
Nashville. However, a high degree of colinearity was
found between geographic location and race in this model.
For example, 84% of Washington, DC, participants were
black, compared to 20% of participants from Nashville.
Accordingly, a second multivariate model was constructed
in which geographic location was controlled by condition-
ing. In this model, black race was the only risk factor sig-
nificantly associated with infection with a resistant H.
pylori strain (Table 6).
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Table 1. Endoscopy findings on patients enrolled in the 
Helicobacter pylori Antimicrobial Resistance Monitoring Project, 
1998–2002
a 
Endoscopic diagnosis  No. of patients (%) 
Stomach erosion  88 (27.0) 
Gastritis  36 (11.0) 
Duodenal ulcers  26 (8.0) 
Esophagitis  26 (8.0) 
Gastric ulcer  26 (8.0) 
Duodenal erosion  24 (7.0) 
Barrett esophagus  9 (3.0) 
Nodularity  8 (2.0) 
Stomach tumor  4 (1.0) 
Bleeding
b  1 (0.3) 
Other diagnosis  27 (8.0) 
aN = 331; H. pylori resistance is not associated with disease phenotype. 
bCause not specified. 
Figure. Resistance of Helicobacter pylori isolates submitted to the
Helicobacter pylori Antimicrobial Resistance Monitoring Project,
1998-2002 (N = 347).1998, n = 7 isolates; 1999, n = 137 isolates.
Resistance to tetracycline was found in 0% of isolates during each
year of the monitoring project.Discussion
The emergence of antimicrobial resistance in H. pylori
represents a serious public health challenge because of the
prevalence of infection and incidence of severe sequelae.
A 12-fold increase in resistance to antimicrobial agents
such as clarithromycin has been documented in cases in
which antimicrobial therapy regimens do not eliminate H.
pylori (9). Once resistance to clarithromycin appears,
cross-resistance to all other macrolides also occurs, which
eliminates the potential for their use in salvage therapies.
In the past 5 years, amoxicillin and tetracycline resistance
has also been described (6,10). 
H. pylori resistance is amply documented in a variety of
study populations. However, most published studies have
been based on cross-sectional designs, not prospective
population-based surveillance of resistance. A meta-analy-
sis of 20 nationwide clinical trials estimated H. pylori
resistance to clarithromycin, metronidazole, and amoxi-
cillin to be 10.1%, 36.9%, and 1.4%, respectively (6).
These findings were also reflected in smaller single-site
studies (11). Resistance rates may be higher in pediatric
populations; for example, a study in Michigan demonstrat-
ed that clarithromycin resistance in pediatric H. pylori
strains was 2.5 times higher than that reported in adults in
the same region and elsewhere in the United States (12). 
Single-site and multicenter surveillance network stud-
ies in Britain, Croatia, the Czech Republic, Turkey,
Greece, Poland, Russia, Slovenia, Turkey, Estonia, Italy,
Bulgaria, Germany, and Belgium have observed primary
metronidazole and clarithromycin resistance with rates as
high as 40.3% and 10.6%, respectively (13–17). A large
prospective surveillance project in northeastern Germany
showed primary metronidazole and clarithromycin resist-
ance rates of 26.2% and 2.2%, respectively, in 1,644 clini-
cal H. pylori isolates collected from 1995 to 2000 (17).
High resistance rates to metronidazole and clarithromycin
have been reported in Portugal, Brazil, Hong Kong, Saudia
Arabia, and Lebanon (18–22). Overall, H. pylori resistance
to metronidazole among single and multicenter surveil-
lance networks is greater than all other resistant antimicro-
bial agents combined.
HARP is the only multicenter network providing ongo-
ing prospective antimicrobial resistance and associated
risk factor data for H. pylori in North America. The first 4
years of data show that resistance to antimicrobial drugs
commonly used to treat H. pylori infections is widespread,
though rates varied from year to year; this finding was true
for both clarithromycin and metronidazole. We speculate
that the precipitous decrease in metronidazole resistance in
2002 could be attributed to the reduction in isolates
received by HARP, which limited the power and represen-
tiveness of our sample.
We performed a two-phased multivariate analysis on
risk factors significantly associated with resistance on uni-
Risk Factors for Antimicrobial Resistance in Helicobacter pylori
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Table 2. Resistance of HARP isolates by region
a 
Amoxicillin,  Tetracycline,  Clarithromycin,  Metronidazole, 








isolates  no. (%)  no. (%)  no. (%)  no. (%)  no. (%)  no. (%)  no. (%) 
Northeast  156  2 (1)  0  23 (15)  47 (30)  54 (35)  9 (6)  63 (40) 
South  92  1 (1)  0  13 (14)  13 (14)  19 (21)  4 (4)  23 (25) 
West  24  0  0  1 (4)  4 (17)  3 (13)  1 (4)  4 (17) 
Midwest  75  0  0  8 (11)  23 (31)  25 (33)  3 (4)  28 (37) 
Total  347  3  0  45  87  101  17  118 
aN = 347; HARP, Helicobacter pylori Antimicrobial Resistance Monitoring Project. 
Table 3. Resistance of HARP H. pylori isolates by site
a 
Amoxicillin,  Tetracycline  Clarithromycin,  Metronidazole, 
Resistant to  
1 agent, 






isolates  no. (%)  no. (%)  no. (%)  no. (%)  no. (%)  no. (%)  no. (%) 
Atlanta, GA  37  0  0  7 (19)  5 (14)  4 (11)  4 (11)  8 (22) 
Nashville, TN  45  1 (2)  0  5 (11)  5 (11)  11 (24)  0  11 (24) 
Galveston, TX  10  0  0  1 (10)  3 (30)  4 (40)  0  4 (40) 
Philadelphia, PA  41  1 (2)  0  6 (15)  15 (37)  16 (39)  3 (7)  19 (46) 
Washington, DC  93  1 (1)  0  15 (16)  31 (33)  35 (38)  6 (7)  41 (44) 
Indianapolis, IN  36  0  0  3 (8)  15 (42)  18 (50)  0  18 (50) 
Detroit, MI  18  0  0  3 (17)  4 (22)  3 (17)  2 (11)  5 (28) 
Cleveland, OH  6  0  0  0  1 (17)  1 (17)  0  1 (17) 
Milwaukee, WI  15  0  0  2 (13)  3 (20)  3 (20)  1 (7)  4 (27) 
Stanford, CA  24  0  0  1 (4)  4 (17)  3 (13)  1 (4)  4 (17) 
New York, NY  22  0  0  2 (9)  1 (5)  3 (14)  0  3 (14) 
aN = 347; HARP, Helicobacter pylori Antimicrobial Resistance Monitoring Project. variate analysis. In the first-phase, multivariate model,
antimicrobial resistance was significantly associated with
previous antimicrobial treatment for H. pylori, and antacid
use was protective. However, in this model, geographic
location was highly collinear with race, which necessitated
the second-phase multivariate model, in which the contri-
bution of race was assessed by conditioning on geographic
location, previous antimicrobial treatment for H. pylori
infection, and antacid use. This model clearly demonstrated
an association between black race and infection with an
antimicrobial-resistant H. pylori. This association may indi-
cate persistent transmission of resistant strains or in vivo
induction of resistance. The association between H. pylori
infection and blacks in the United States has been amply
documented (2,3). However, the association between inci-
dence of H. pylori resistance and black race is new. The
biologically plausible association between previous antimi-
crobial use and resistance approached significance in the
second-phase model; however, many study participants
could not recall whether they were previously treated. This
model does not rule out an independent association
between geographic location and resistance. Enrollment of
additional participants in HARP may sufficiently enhance
the statistical power of the study to show such an associa-
tion, while enrollment in sites serving a more racially
diverse population may help clarify the contributions of
geographic location as a risk factor for resistant infection.
This study has several limitations. While drawn from
various regions in the continental United States, the 11
HARP sites represent a convenience sample of academic
medical centers that is not truly representative of the U.S.
population. Some participating sites enrolled more patients
per month than others, so that cumulative data are biased
towards individual study sites. Most of the participating
hospital sites serve adult populations, and thus the results
largely reflect resistance incidence towards adult patients.
Patients undergoing endoscopy for H. pylori-related illness
constitute a minority of infected persons, whose clinical
condition and H. pylori-resistance status may not be repre-
sentative of the total population with underlying H. pylori
infection. Although this trend has not been documented,
RESEARCH
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Table 4. Univariate analysis of risk factors for resistance to >1 antimicrobial agent among Helicobacter pylori isolates submitted to 
HARP, 1998–2002
a 
Proportion of patients harboring  
resistant H. pylori isolate 
Risk factor  Exposed, no. (%)  Unexposed, no. (%)  Odds ratio (95% CI) 
Zantac use 12 mo before EGD  25 (48)  89 (32)  2.0 (1.1–3.6)
b 
Tums use 12 mo before EGD  19 (51)  95 (32)  2.2 (1.1–4.4)
b 
Tums use 30 d before EGD  12 (55)  102 (33)  2.4 (>1.0–5.8)
b 
Mylanta use 12 mo before EGD  4 (15)  110 (36)  0.3 (0.1–1.0) 
Took antibiotic 12 mo before EGD  29 (43)  68 (34)  1.5 (0.9–2.6) 
Past treatment of H. pylori infection with        
PPI  5 (71)  109 (34)  4.9 (1.0–26) 
Clarithromycin  5 (83)  109 (33)  9.9 (1.1–86) 
Treatment for H. pylori a second time in the past 5 years  11 (65)  107 (32)  3.8 (1.4–11) 
Treatment of H. pylori infection more than once with       
PPI  8 (80)  106 (33)  8.1 (1.7–39) 
Clarithromycin  8 (80)  106 (33)  8.1 (1.7–39) 
Age >57 years  50 (31)  68 (37)  0.8 (0.5–1.2) 
Race/ethnicity       
Black  67 (39)  51 (29)  1.6 (1.0–2.4) 
Hispanic  2 (11)  116 (35)  0.2 (0.1–1.0) 
Male sex  65 (31)  47 (42)  0.6 (0.4–1.0) 
HARP site       
New York, NY  3 (14)  115 (35)  0.3 (0.1–1.0) 
Palo Alto, CA  4 (17)  114 (35)  0.4 (0.1–1.1) 
Atlanta, GA  8 (22)  110 (36)  0.5 (0.2–1.1) 
Nashville, TN  11 (24)  107 (35)  0.6 (0.3–1.2) 
aN = 347; HARP, Helicobacter pylori Antimicrobial Resistance Monitoring Project; EGD, esophagogastro -duodenal endoscopy; PPI, proton pump inhibitor; 
CI, confidence interval. 
bThese risk factors were not considered for multiv ariate analysis because of small cell-size differences between subjects with a resistant  H. pylori infection 
and those without. 
Table 5. Phase I multivariate analysis of risk factors for  
resistance to >1 antimicrobial agent among H. pylori isolates 
submitted to HARP, 1998–2002
a 
Exposure  Odds ratio (95% CI) 
Patient treated another time for infection  6.0 (2.0–20) 
Took Mylanta in last 12 mo  0.3 (0.1–0.8) 
HARP site   
New York, NY  0.2 (0.1–0.7) 
Palo Alto, CA  0.2 (0.1–0.7) 
Atlanta, GA  0.2 (0.1–0.6) 
Nashville, TN  0.4 (0.2–0.9) 
aN = 347; HARP, Helicobacter pylori Antimicrobial Resistance Monitoring 
Project; CI, confidence interval. many public health analysts suspect that the proportion of
H. pylori infections diagnosed and treated in academic
medical centers is decreasing compared with those in
community practices. We suspect that this trend may have
accounted for the reduced number of isolates submitted to
HARP over time. Although these limitations primarily
affected our sample size and how the sample represented
the population, they did not invalidate the epidemiologic
significance of the results generated from this study. 
Given the limited population-based surveillance data
on H. pylori resistance, HARP offers the best available
data on H. pylori resistance in the United States. The accu-
racy and usefulness of this prospective, multicenter net-
work can be enhanced in a number of ways. Increasing the
number of HARPsites will improve geographic and demo-
graphic representation. Given the fact that only 12 study
participants <12 years of age were included, enrollment of
pediatric-care sites will improve the age representation of
the HARP cohort. This feature is particularly important
considering the increasing number of reports that describe
higher resistance rates in pediatric strains compared to
those isolated from adults, particularly resistance to
macrolides (12,23). Enrolling study participants in com-
munity practices will provide data on resistance rates in H.
pylori isolates from infected persons not treated at academ-
ic medical centers, a population in which resistance rates
in H. pylori are unknown and may differ significantly from
the current HARP cohort. Future HARP findings may
serve as the basis for specific therapeutic recommenda-
tions and pretreatment antimicrobial susceptibility testing
in high-risk populations.
In summary, we have shown that antimicrobial resist-
ance in clinical H. pylori isolates is extensive, that it varies
from year to year, and that resistant isolates are more com-
mon among blacks. Ongoing, prospective surveillance of
H. pylori resistance is essential to ensure that appropriate
data are available to guide the choice of therapy, particu-
larly in high-risk populations.
Mr. Duck is a surveillance epidemiologist in the Division of
Bacterial and Mycotic Diseases, National Center for Infectious
Diseases, Centers for Disease Control and Prevention. His pri-
mary research interests include Helicobacter pylori antimicrobial
resistance, botulism, and bioinformatics. 
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